Sie befinden sich hier:
The Department of Internal Medicine – Cardiology is conducting the multicentric RESTORE-HF study of elamipretide in patients with heart failure with preserved ejection fraction (HFpEF). "Elamipretide improves the function of the mitochondria and therefore the energy balance of the heart muscle cells and represents an entirely new approach to the treatment of heart failure. In this multicentric phase IIa study patients with HFpEF will be treated with elamipritide for the first time worldwide, which is scientifically very innovative," explains Prof. Burkert Pieske, chair of the steering committee. The study is being coordinated by Dr. Hans-Dirk Düngen and performed by institutions belonging to the Berlin Cardiovascular Research Institutes (BCRI), with the cooperation of the Echo Core Lab (head, Dr. Elisabeth Pieske-Kraigher) and the Center for the Coordination of Clinical Studies (head, Dr. Olaf Bender), with external partners in Germany and Serbia.
Stealth Biotherapeutics is the study sponsor.
Heart Failure Congress 2016, Florence, Italy
The BCRI team participated in the European Society of Cardiology Heart Failure Congress in Florence this year and reported the main results of their recent research.
Prof. Burkert Pieske, chair of BCRI, presented the overall research highlights on the topic chronic heart failure and gave lectures on the drug vericiguat and diagnostic criteria in heart failure with preserved ejection fraction (HFpEF). He also presented the main results of the SOCRATES-PRESERVED study in the Late Breaking Clinical Trial session.
BCRI's executive director, Associate Prof. Hans-Dirk Düngen, presented results from three studies carried out at the trial site. He also held a rapid-fire presentation on the topic of survival in HFpEF vs HFrEF patients after beta-blocker titration (new analysis from the CIBIS-ELD trial). BCRI's CPET and CRU director, Prof. Frank Edelmann and his team presented new results from ALDO-DHF and Ex-DHF trials.
RESTORE-HF Echocardiography training event in Berlin
On 14.04.2016 echocardiographic training for the RESTORE-HF study took place in Berlin for the 30 study doctors and principle investigators from Germany and Serbia. They were instructed by staff of Charité – Universitätsmedizin Berlin and the Coordination Center for Clinical Trials of the Echo Core Lab. RESTORE-HF is to test a new drug to treat heart failure patients in Germany and Serbia.
The echocardiographic evaluation of the study will be done in close cooperation with the Berlin Echo Core Lab. The study is sponsored by Stealth Biotherapeutics, Boston.